Abstract
BackgroundRituximab, a chimeric monoclonal anti-CD20 antibody, is approved to be infused over 4hours and 15minutes, due to the potential for infusion reactions. The risk of infusion reactions has been shown...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have